Surgical therapy remains the treatment of choice for resectable non -small-cell lung cancer (NSCLC) . However, postoperative survival is far from acceptable , except for patients with stage IA tumors. Furthermore, the efficacies of postoperative adjuvant therapies have not been well established . Under these circumstances, induction chemotherapy has attracted widespread attention from clinicians and several comparative clinical studies on induction chemotherapy have reported favorable results . Therefore, the authors decided to conduct a pilot study to evaluate the efficacy and safety of triple induction chemotherapy for NSCLS using two new anti-cancer drugs , vinorelbine
(VNR) and docetaxel (TXT), plus cisplatin (CDDP). Methods and Results. Thirty-three patients with unresectable NSCLC, who underwent triple chemotherapy and 25 patients with resectable NSCLC, who underwent induction chemotherapy (IC) , were enrolled in this study. The overall NSCLC histological types consisted of 24 adenocarcinomas (Ad.), 28 squamous cell carcinomas (Sq.) , and 6 large cell carcinomas (La.). The clinical stages of the patients were as follows: stage IIA, 3 patients; stage IIB, 8 patients; stage IIIA, 14 patients; stage IIIB, 18 patients; and stage IV, 15 patients. Among the IC cases, 9 patients had Ad., 13 patients had Sq., and 3 patients had La.. The clinical stages of the patients who underwent IC were as follows: stage IIA, 3 patients; stage IIB, 7 patients; stage IIIA, 12 patients; and stage IIIB, 3 patients.
The IC regimen consisted of VNR (25 mg/m2) administered on day 1, and TXT (60 mg/m2) administered on day 2; to ameliorate the adverse effects of these drugs, a total of 80 mg/m2 of CDDP was administered for 5 consecutive days beginning on day 2 (25 mg/day for first 4 days and the remainder on day 6). The overall response rate was 46.6% (4 complete responses and 23 partial responses) , and the number of chemotherapy courses was 104 (1.8 courses per person, on average). In 14 of the 25 IC subjects, down-staging was observed; 20 cases subsequently received curative resections. The resected primary lesions and dissected lymph nodes were histologically evaluated to evaluate the efficacy of the treatment. Based on this evaluation, the histopathological effects of Ef.3 and Ef.2 were reported to be 10% and 40%, respectively. However, in 4 out of 12 cases, where metastasis to the lymph nodes decreased after chemotherapy, residual cancer was histologically observed in the lymph nodes. The median survival time for the 33 patients with unresectable NSCLC was 6.4 months. The 1-year and 2-year survival rates were 31.2% and 13.4% respectively. Among the 25 patients who underwent IC, the 1-year and 2-year survival rates were 95.2% and 67.9%, respectively. The main adverse reaction related to hematological toxicity among these subjects was leukocytopenia. Grade 3/4 leukocytopenia was observed in 93.0% of the patients, but was ameliorated by granulocyte colony-stimulating factor (G-CSF) treatment. Other nonhematological toxicity-related adverse effects were nausea and vomiting. Grade 3 nausea and vomiting was observed in 28.1% and 24.6% of the patients, respectively. These adverse reactions were ameliorated by the administration of antivomiting agents (5-HT3, metoclopramide) and liquid perfusions. No significant nephrotoxicity was observed. Conclusion. Triple chemotherapy using VNR, TXT, and CDDP was tolerated by subjects witha good performance status who were under the age of 70 years; this therapy might be effective for preoperative induction chemotherapy. Table  5 . Toxicity 
